Interviews with the world’s key opinion leaders in cancer

TagECC 2013 Amsterdam

The TH3RESA study: TDM-1 doubles progression free survival in HER-2 positive refractory metastatic breast cancer.

November 19, 2013

AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment...

TagECC 2013 Amsterdam

The TH3RESA study: TDM-1 doubles progression free survival in HER-2 positive refractory metastatic breast cancer.

Menu